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Histologically, Alzheimer’s disease (AD) is characterized by senile plaques and cerebrovascular amyloid deposits. In previous
studies we demonstrated that in AD patients, amyloid-β (Aβ) peptide also accumulates in choroid plexus, and that this process
is associated with mitochondrial dysfunction and epithelial cell death. However, the molecular mechanisms underlying Aβ
accumulation at the choroid plexus epithelium remain unclear. Aβ clearance, from the brain to the blood, involves Aβ carrier
proteinsthatbindtomegalin,includinggelsolin,aproteinproducedspeciﬁcally bythechoroidplexusepithelialcells.Inthisstudy,
we show that treatment with gelsolin reduces Aβ-induced cytoskeletal disruption of blood-cerebrospinal ﬂuid (CSF) barrier at the
choroid plexus. Additionally, our results demonstrate that gelsolin plays an important role in decreasing Aβ-induced cytotoxicity
by inhibiting nitric oxide production and apoptotic mitochondrial changes. Taken together, these ﬁndings make gelsolin an
appealing tool for the prophylactic treatment of AD.
1.Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized by a progressive loss of cognitive function
and is associated with neuropathological hallmarks that
include amyloid plaques, neuroﬁbrillary tangles, synaptic
loss,andneurodegeneration.Senileplaquesmainlyconsistof
an extracellular accumulation of the 40–42-aminoacid long
peptideamyloidβ (Aβ)[1,2],althoughintracellulardeposits
of Aβ have also been reported [3, 4]. Besides accumulating in
thebrainparenchyma,Aβalsoaccumulatesinchoroidplexus
epithelial cells [5] and in cerebrovascular walls, where it
inducesblood-brain barrierdisruption [6–8].Severalstudies
have shown that Aβ1–40 and Aβ1–42 alter transmembrane
and cytoplasmic tight junction proteins in brain microvessel
endothelial cells, including ZO-1, which ultimately leads to
disruption in the integrity of the blood-brain barrier [9, 10].
In support of these ﬁndings, recent results from our
laboratory have suggested direct relationship between Aβ
accumulation at the choroid plexus epithelium and the
development of functional and structural dysfunctions [5,
11]. In addition, we demonstrated the existence of a link
between Aβ-induced choroid plexus cell death, increased
production of nitric oxide (NO), and mitochondrial dys-
function in the choroid plexus of patients with AD and
amyloid precursor protein (APP)/PS1 mice [11].
The choroid plexus, which is made up of a single epithe-
lial cell layer, is responsible for producing cerebrospinal ﬂuid
(CSF) and constitutes the blood-CSF barrier. Additionally,
choroid plexus cells produce proteins involved in several
processes important for normal brain function, such as
prevention of Aβ ﬁbrillization. One of such proteins is
gelsolin [12], which is a potent actin-regulatory protein that
controlscytoskeletalassemblyanddisassembly[13].Gelsolin
can be found both as an intrinsic cytoplasmic protein and
as a secreted protein [14]. Besides controlling formation of
cytoplasmic actin ﬁlaments, gelsolin plays an important role
in apoptosis and amyloidosis. The secretory form of gelsolin
is known to bind Aβ under normal physiological conditions
[15], inhibit the ﬁbrillation of Aβ, and deﬁbrillize preformed2 Journal of Biomedicine and Biotechnology
ﬁbrils of this peptide [16]. Some groups have suggested that
gelsolin could be used in the prophylactic treatment of AD as
Aβ sequestering agent [17, 18].
In this study, we hypothesize that the secreted form of
gelsolin could be an eﬀective therapeutic approach for the
preservation of blood-CSF barrier integrity and function,
and thus an attractive tool for the prophylactic treatment
of AD. To test the hypothesis that secreted gelsolin can
reduce Aβ cytotoxicity on choroid plexus epithelium, we
analyzed cytoskeletal alterations, including the distribution
andexpressionofZO-1.Inaddition,weassessedAβ-induced
NO production, cell death, and mitochondrial changes in
choroid plexus epithelial cells.
2. Methods
Cell Culture. Epithelial cell monolayers from P3-P5 Wistar
rats were prepared as described previously [19]. Cells were
grown to conﬂuence for 5–7 days and serum starved for
2 hours. Human analog peptides corresponding to Aβ1–40,
Aβ1–42,o rs c r a m b l e dA β1–42(5μg/mL; AnaSpec, Inc.), and
gelsolin, extracted from bovine plasma (5μg/mL; Sigma),
were added. Forty-eight hours after stimulation, cells were
either ﬁxed for immunocytochemical analysis or homoge-
nized for immunoblot determination.
Antibodies. The following antibodies were used: mouse
monoclonal anti-Aβ1–40 (Chemicon), rabbit polyclonal anti-
Aβ1–42 (Chemicon), goat polyclonal anti-megalin (Santa
Cruz Biotechnology), mouse monoclonal anti-gelsolin
(Sigma), mouse monoclonal anti-pSer (Sigma), goat poly-
clonal anti-ZO-1 (Santa Cruz Biotechnology), mouse mon-
oclonal anti-CoxVa (Molecular Probes), BIODIPY FL phal-
lacidin (Invitrogen), Alexa-coupled (Molecular Probes), and
HRP-conjugated (Bio-Rad).
Western-Blot Analysis. Western-blot (WB) analysis and
immunoprecipitation were performed as described previ-
ously [19]. WB membranes were reblotted with the same
antibody used for immunoprecipitation, and to normalize
forproteinload.Densitometricanalysiswasperformedusing
ImageJ software (NIH). Nonimmune normal rabbit serum
was used as a control for immunoprecipitation studies.
Blue Native Electrophoresis. Mitochondrial membranes were
isolated according to the method described by Nijtmans
et al. [20]. Enzyme activity of mitochondrial complexes
from choroid plexus epithelial cell cultures was measured
as described previously [11]. Gels were washed in distilled
water, scanned, photographed immediately, and quantiﬁed
with the aid of ImageJ software (NIH) [11].
Determination of NO Production. For NO detection, choroid
plexus epithelial cell cultures were processed using the Nitric
Oxide Colorimetric Assay Kit (BioVision, Inc.) as described
previously [11].
Cell Death Quantiﬁcation. After 48-hour incubations with
Aβ1–42 and gelsolin, DNA fragmentation in choroid plexus
epithelial cells undergoing apoptosis was detected with a
Cell Death Detection ELISAPLUS kit (Roche) as described
previously [11].
3. Results
Gelsolin Binds to Megalin and Forms a Complex with Aβ. We
observed that megalin from rat choroid plexus cells binds
to Aβ1–40 and to gelsolin (Figure 1(a)). Furthermore, our
results indicate that both the cytoplasmic and the secreted
forms of gelsolin bind to megalin (Figure 1(a), top panel).
Theseﬁndingswerecorroboratedbyimunoprecipitationand
double immunostaining, which showed that gelsolin co-
localizes with megalin and Aβ in choroid plexus epithelial
cells (Figure 1(b)).
Gelsolin Inhibits Aβ-Induced Disruption on Choroid Plexus
Epithelial Cell Cytoskeleton. Choroid plexus epithelial cells
exposed to Aβ1–42 for 48 hours showed a disrupted plasma
membrane pattern of ZO-1 with relocation of this protein
to the cytoplasm (Figure 2(a)). Aβ1–42-induced disruption
of epithelial barrier integrity was also conﬁrmed by an
increase on serine phosphorylation rate. Immunoprecipita-
tion with anti-ZO-1, followed by immunoblotting with anti-
pSer, showed an increase in serine ZO-1 phosphorylation
and a reduction in ZO-1 expression in choroid plexus
epithelialcells(Figure 2(b)).Wefoundthatcoadministration
of gelsolin restored these Aβ1–42-induced eﬀects (Figures
2(a) and 2(b)). Moreover, this Aβ1–42-induced eﬀect on the
behavior of this tight junction protein was also accompanied
by cytoskeletal disruption, as we observed the formation
actin stress ﬁbers (Figure 2(c), middle panel). The immuno-
cytochemical analysis revealed a restoration of cytoskeletal
assembly when gelsolin was added to the culture medium
(Figure 2(c), right panel).
Gelsolin Inhibits Aβ-Induced NO Production and Neuronal
Death in Choroid Plexus Epithelial Cells. Gelsolin blocked
Aβ1–42-induced NO production by cultured choroid plexus
epithelial cells after 48 hours of treatment (Figure 3(a)). In
vitro, Aβ1–42-induced cell death in choroid plexus epithelial
cells was also reversed after 48 hours of gelsolin administra-
tion (Figure 3(b)).
Gelsolin Increases Mitochondrial Respiratory Chain Activity in
Choroid Plexus Epithelial Cells. When gelsolin was added to
the choroid plexus culture, an increased activity of complex
IVwasobservedascomparedwithcontrolcells(Figure 3(c)).
Moreover, gelsolin was able to reverse the inhibitory eﬀect of
Aβ in complex IV activity (Figure 3(c)). WB performed to
assessproteinlevelalterationsrevealedaparallelactivationin
complex IV, reﬂected by an increase in Cox Va subunit levels
(Figure 3(c)).Journal of Biomedicine and Biotechnology 3
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Figure 1: Gelsolin expression in choroid plexus epithelial cells. (a) Antimegalin immunoprecipitation of rat choroid plexus cell extracts,
followed by blotting with respective antibodies, revealed an association between megalin, endogenous gelsolin, the exogenously added
secreted gelsolin form, and the exogenously added Aβ. Immunoprecipitation with nonspeciﬁc serum showed no unspeciﬁc Aβ association.
Binding of gelsolin with exogenously added Aβ was also observed. Representative blots are shown (n = 4). (b) Megalin colocalized with
gelsolin and exogenously added Aβ in choroid plexus cultures. Confocal images also show gelsolin colocalization with Aβ. Scale bars =
10μm. IP: Immunoprecipitation; NRS: normal rabbit serum.
4. Discussion
Gelsolin, an actin-regulatory protein, exists both as an
intracellular and extracellular protein [14] and is present
in all nervous system cell types, including neurons [21]a n d
choroid plexus [12]. Our ﬁndings indicate that secreted
gelsolin is involved in the pathology of AD through the
regulation of brain Aβ and its neurotoxic eﬀects. Plasma
gelsolin has been found to bind and reduce brain Aβ
[15, 17, 18]. In the present study we had conﬁrmed
the formation of a complex between cytoplasmic and
secreted gelsolin with Aβ, accordingly with previously
published studies [15, 22]. Our current results extend these
observations, suggesting that megalin, an endocytic receptor
involved in Aβ clearance [23–27], has a functional role
in the formation of this complex. We show that megalin
binds Aβ/gelsolin complex in the choroid plexus epithelium,
suggesting a role in clearance of Aβ from CSF to the blood.
The latter is not surprising in view of megalin’s ability to
transport a large variety of proteins [28].
Abnormalitiesincytoskeletalorganizationareacommon
feature of many neurodegenerative disorders, including AD.
Interestingly, Aβ1–42-induced cytoskeletal alterations known
to be associated with the proteolytic degradation of the
tightjunction-associatedproteinZO-1[10,11]werereversed
after secreted gelsolin treatment, with relocation from the
cytoplasm to the original position in the cell membrane of
choroidplexusepithelialcells.Inaddition,ourresultssuggest4 Journal of Biomedicine and Biotechnology
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Figure 2: Secreted gelsolin inhibits Aβ-induced disruption on choroid plexus epithelial cell cytoskeleton. (a) Representative confocal images
of choroid plexus conﬂuent monolayer labeled with anti-ZO-1 antibody. Under control conditions, ZO-1 immunostaining is distributed
along the plasma membrane. In contrast, after exposure to Aβ1–42 for 48 hours, a disruption of the plasma membrane pattern of ZO-1 was
observed, resultingin increased cytoplasmic localization. Note the ability of gelsolin treatment to prevent this Aβ-induced alteration in ZO-1
pattern.(n = 3).(b)Aβ1–42 treatmentresultedinincreasedserinephosphorylationofZO-1anddecreasedZO-1expressioninchoroidplexus
epithelial cells. Gelsolin coadministration markedly attenuated Aβ1–42 alteration in ZO-1 (n = 3). (c) BIODIPY FL phallacidin staining of
choroid plexus epithelial cells showed a disruption of the actin cytoskeleton after treatment with Aβ1–42 for 48 hours, and reversion when
gelsolin was simultaneously added. Magniﬁcation: ×40. Scale bars = 10μm.
that the secretory form of gelsolin prevents the internaliza-
tionofZO-1byblockingserinephosphorylation,ashasbeen
also demonstrated in other studies [29–31]. The presence of
structures characterized by aggregates of polymerized actin
(F-actin) has been described in AD [32]. Also, F-actin levels
have been shown to increase in hippocampal neurons treated
with Aβ [33]. Furthermore, cortical neurons expressing the
APP intracellular domain suﬀer from pronounced changes
in the organization of the actin cytoskeleton, including
destabilization of actin ﬁbers [34]. We found that ﬁbrillar
Aβ1–42 also caused alterations in cytoskeletal actin in choroid
plexus epithelial cells, as reﬂected by an increase in the
F-actin content, and that gelsolin was able to protect
against this eﬀect. In this way, gelsolin contributes to the
maintenanceofthechoroidplexusmonolayerandtheblood-
CSF barrier integrity. A possible explanation for these eﬀects
could be that Aβ increases metalloproteinase 9 [11, 35,
36], which is capable of cleaving cytoplasmic gelsolin [37],
thereby resulting in the destabilization of actin ﬁlaments and
the disruption of tight junctions. Secreted gelsolin, which
bindsandsequestratesAβ,wouldthenbeabletopreventand
diminish Aβ toxic eﬀects.
On the other hand, our results also indicate that gel-
solin prevents Aβ-induced cell death and NO production
from choroid plexus cell cultures. Using several models
of neuronal cell death, others studies have demonstrated
that cytoplasmic gelsolin has antiapoptotic properties that
correlate with its dynamic actions on the cytoskeleton [38].Journal of Biomedicine and Biotechnology 5
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Figure 3: Secreted gelsolin expression modulates NO production and cell death in choroid plexus epithelial cells. (a) Choroid plexus
epithelial cells treated with Aβ1–42 for 48 hours exhibited a signiﬁcantly enhanced NO production compared with untreated cells. Secreted
gelsolin coadministration completely blocked this eﬀect (n = 3); ∗∗P<. 01. (b) Increased cell death was observed in choroid plexus
cell cultures 48 hours after Aβ1–42 treatment, and gelsolin addition totally reversed this toxic eﬀect (n = 3); ∗P<. 05. (c and d) Aβ1–42
treatment reduced mitochondrial complex IV in-gel activity in choroid plexus epithelial cells, whereas secreted gelsolin administration
increased complex IV activity and reversed this decrease in Aβ1–42-induced activity. Blue native analysis of these culture samples showed
altered protein expression in the mitochondrial complex IV. Representative blue native blots and quantitative histograms are shown (n = 4
per group); ∗P<. 05.
Indeed, gelsolin-null neurons have enhanced cell death [39]
and increased vulnerability to glutamate toxicity [40]. In a
previous study we reported that Aβ-induced mitochondrial
dysfunction could ultimately activate a programmed cell
death pathway in the choroid plexus epithelial cells [11].
In this study, we show that secreted gelsolin prevents
Aβ-induced cell death by increasing enzyme activity of
the respiratory chain complex IV in the choroid plexus
epithelial cells. These observations are in line with other
studies showing an Aβ-induced reduction of mitochondrial
membrane potential by cytoplasmic gelsolin [41, 42]. The
intracellular form of gelsolin is associated to the mitochon-
drial membrane, where it can inhibit Aβ-induced loss of
mitochondrial membrane potential, cytochrome c release,
and regulate voltage-dependent channels [40, 41]. Since
extracellular gelsolin has also been detected in CSF, where its
concentration is signiﬁcantly altered in certain neurological
conditions [43], this extracellular isoform of gelsolin may
well reduce choroid plexus Aβ-induced pathology in a
similar manner to intracellular gelsolin [17, 18].
In conclusion, our results demonstrate that secreted
gelsolin can modulate Aβ-induced alterations in the blood-
CSF barrier. We suggest that secreted gelsolin have a
neuroprotective role against Aβ neurotoxicity. In summary,
enhancement of gelsolin levels may represent a novel way to
protect against Aβ neurotoxicity and, in the future, could be
considered a potential therapeutic strategy for the treatment
of patients with AD.6 Journal of Biomedicine and Biotechnology
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